Nuformix plc (LON:NFX – Get Free Report) traded up 8.7% during mid-day trading on Wednesday . The stock traded as high as GBX 0.09 ($0.00) and last traded at GBX 0.09 ($0.00). 3,331,248 shares were traded during trading, a decline of 96% from the average session volume of 74,219,031 shares. The stock had previously closed at GBX 0.08 ($0.00).
Nuformix Stock Performance
The company has a market cap of £1.18 million, a PE ratio of -2.92 and a beta of 1.22. The firm’s 50 day moving average is GBX 0.07 and its 200-day moving average is GBX 0.09.
Nuformix (LON:NFX – Get Free Report) last posted its earnings results on Wednesday, January 29th. The company reported GBX (0.46) (($0.01)) earnings per share for the quarter.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Further Reading
- Five stocks we like better than Nuformix
- Are Penny Stocks a Good Fit for Your Portfolio?
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
- The Most Important Warren Buffett Stock for Investors: His Own
- Gold’s Ascent: Can Miners and ETFs Take Investors to $3,000?
- What Do S&P 500 Stocks Tell Investors About the Market?
- Medtronic’s Expansion Gains Momentum—Time for a Market Shift?
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
